




FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

STEVEN L. HIGHLANDER
PARTNER
SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3184
TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

January 28, 2004

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:	
January 28, 2004	
Date	Steven L. Highlander

MS DD

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

RE: *U.S. Patent Application No. 10/670,766 entitled "TREATMENT OF PATIENTS WITH MULTIPLE SCLEROSIS BASED ON GENE EXPRESSION CHANGES IN CENTRAL NERVOUS SYSTEM TISSUES" – Fernando Dangond et al.*
Our reference: PART:005US
BWH No.: 835


Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references C1-C21.

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/PART:005US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,


Steven L. Highlander
Reg. No. 37,642

SLH/kmv
Encl.: as noted



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Fernando Dangond *et al.*

Serial No.: 10/670,766

Filed: September 25, 2003

For: TREATMENT OF PATIENTS WITH
MULTIPLE SCLEROSIS BASED ON
GENE EXPRESSION CHANGES IN
CENTRAL NERVOUS SYSTEM
TISSUES

Group Art Unit: 1632

Examiner: Unknown

Atty. Dkt. No.: PART:005US

CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

January 28, 2004

Date

Steven L. Highlander

INFORMATION DISCLOSURE STATEMENT

MS DD

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/PART:005US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: January 28, 2004

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

PART:005US

10/670,766

List of Patents and Publications for Applicant's

Applicant

Fernando Dangond *et al.*

INFORMATION DISCLOSURE STATEMENT

Filing Date:

September 25, 2003

Group:

1632

(Use several sheets if necessary)

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Barcellos <i>et al.</i> , "CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis," <i>Immunogenetics</i> , 51:281-288, 2000.
	C2	Carlin <i>et al.</i> , "Involvement of apolipoprotein E in multiple sclerosis: absence of remyelination associated with possession of the APOE ϵ 2 allele," <i>J. Neuropathol. Exp. Neurol.</i> , 59(5):361-367, 2000.
	C3	Chabas <i>et al.</i> , "The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease," <i>Science</i> , 294:1731-1735, 2001.
	C4	Chataway <i>et al.</i> , "Evidence that allelic variants of the spinocerebellar ataxia type 2 gene influence susceptibility to multiple sclerosis," <i>Neurogenetics</i> , 2:91-96, 1999.
	C5	Fernandez-Arquero <i>et al.</i> , "Primary association of a TNF gene polymorphism with susceptibility to multiple sclerosis," <i>Neurology</i> , 53:1361-1363, 1999.
	C6	Fiten <i>et al.</i> , "Microsatellite polymorphisms in the gene promoter of monocyte chemotactic protein-3 and analysis of the association between monocyte chemotactic protein-3 alleles and multiple sclerosis development," <i>J. Neuroimmunol.</i> , 95:195-201, 1999.
	C7	Fukazawa <i>et al.</i> , "CTLA-4 gene polymorphism may modulate disease in Japanese multiple sclerosis patients," <i>J. Neurol. Sci.</i> , 171:49-55, 1999.
	C8	Gade-Andavolu <i>et al.</i> , "Association between the γ -amniobutyric acid A3 receptor gene and multiple sclerosis," <i>Arch. Neurol.</i> , 55:513-516, 1998.

25359147.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

PART:005US

Serial No.

10/670,766

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Fernando Dangond *et al.*

Filing Date:

September 25, 2003

Group:

1632

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C9	Hashimoto <i>et al.</i> , "Immunoglobulin heavy chain variable region polymorphisms and multiple sclerosis susceptibility," <i>J. Neuroimmunol.</i> , 44:77-84, 1993.
	C10	Jacobsen <i>et al.</i> , "A point mutation in PTPRC is associated with the development of multiple sclerosis," <i>Nat. Genetics</i> , 26:495-499, 2000.
	C11	Lock <i>et al.</i> , "Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis," <i>Nature Medicine</i> , 8(5):500-508, 2002.
	C12	Lucotte <i>et al.</i> , <i>Mult. Scler.</i> , "TNF-alpha polymorphisms in multiple sclerosis: no association with -238 and -308 promoter alleles, but the microsatellite allele a11 is associated with the disease in French patients," 6:78-80, 2000.
	C13	Luomala <i>et al.</i> , "Plasminogen activator inhibitor 1 gene and risk of MS in women," <i>Neurology</i> , 54:1862-1864, 2000.
	C14	Miterski <i>et al.</i> , "The interferon gene cluster: a candidate region for MS predisposition? Multiple Sclerosis Study Group," <i>Genes Immun.</i> , 1:37-44, 1999.
	C15	Mycko <i>et al.</i> , "Multiple sclerosis: the frequency of allelic forms of tumor necrosis factor and lymphotixin-alpha," <i>J. Neuroimmunol.</i> , 84:198-206, 1998.
	C16	Mycko <i>et al.</i> , "Multiple sclerosis: the increased frequency of the ICAM-1 Exon 6 gene point mutation genetic type K469," <i>Ann. Neurol.</i> , 44:70-75, 1998.
	C17	Niino <i>et al.</i> , "Estrogen receptor gene polymorphism in Japanese patients with multiple sclerosis," <i>J. Neurol., Sci.</i> , 179:70-75, 2000.
	C18	Tienari <i>et al.</i> , "Genetic susceptibility to multiple sclerosis linked to myelin basic protein gene," <i>Lancet</i> , 340(8826):987-991, 1992.
	C19	Vandenbroeck <i>et al.</i> , "High-resolution analysis of IL-6 minisatellite polymorphism in Sardinian multiple sclerosis: effect on course and onset of disease," <i>Genes Immun.</i> , 1(7):460-463, 2000.
	C20	Walter <i>et al.</i> , "Susceptibility to multiple sclerosis is associated with the proximal immunoglobulin heavy chain variable region," <i>J. Clin. Invest.</i> , 87:1266-1273, 1991.
	C21	Whitney <i>et al.</i> , "Analysis of gene expression in multiple sclerosis lesions using cDNA microarrays," <i>Annals of Neurology</i> , 46(3):425-428, 1999.

25359147.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.